Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases.
Daniel Levitt, executive vice president of R&D at Cerimon, said: “Basiliximab has the potential to significantly improve the quality of life for this group of uveitis patients and reduce adverse events often associated with current treatments that include corticosteroids and other immunosuppressive therapies.”